This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
by Zacks Equity Research
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
biotechnology biotechs earnings medical pharmaceuticals
Markets Stay Lower on Valuation Questions: AI, etc.
by Mark Vickery
We've entered the rapid-pace phase of Q3 earnings season, where results tend to come in more blended than they do for the earlier-reporting sectors.
biotechnology earnings semiconductor tech-stocks
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
by Zacks Equity Research
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
biotechnology biotechs earnings medical pharmaceuticals
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
biotechnology biotechs earnings medical pharmaceuticals
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
by Zacks Equity Research
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
biotechnology biotechs earnings-preview medical pharmaceuticals
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
biotechnology biotechs earnings medical pharmaceuticals
Viatris to Report Q3 Earnings: Is a Beat in the Cards for the Stock?
by Zacks Equity Research
VTRS is set to report Q3 results, with brand strength offsetting generics pressure and a model hinting at an earnings beat.
biotechnology earnings medical pharmaceuticals
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
ZYME, NKTR, ANIP, and PCRX are poised for potential Q3 earnings surprises as the biotech sector shows strong momentum.
biotechnology biotechs earnings medical pharmaceuticals